UK Markets open in 5 hrs 8 mins

Biomea Fusion, Inc. (BMEA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.38-1.65 (-18.27%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close9.03
Open9.98
Bid7.38 x 1200
Ask7.72 x 800
Day's range7.14 - 9.92
52-week range7.00 - 22.22
Volume231,148
Avg. volume186,268
Market cap214.351M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.54
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.00
  • Simply Wall St.

    Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • Simply Wall St.

    How Many Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Do Institutions Own?

    The big shareholder groups in Biomea Fusion, Inc. ( NASDAQ:BMEA ) have power over the company. Large companies usually...

  • Motley Fool

    2 Hot Biotech IPOs to Consider

    Especially for companies that are expected to be growing right out of the gate, getting in during the market's initial feeding frenzy sometimes means buying a stock when it's as cheap as it will ever be. In this vein, Recursion Pharmaceuticals (NASDAQ: RXRX) and Biomea Fusion (NASDAQ: BMEA) are a pair of biotechs that had their IPOs last week, and both have unique value for investors that could make them worth a (speculative) buy. Recursion's information technology-heavy approach to drug discovery could make it a rising star on the basis of its already extensive list of development collaborations alone.